U.S. Markets closed

iSpecimen Inc. (ISPC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.7200-0.6100 (-11.44%)
At close: 04:00PM EST
4.7800 +0.06 (+1.27%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.3300
Bid4.7200 x 2200
Ask4.7800 x 1100
Day's Range4.7000 - 5.3999
52 Week Range4.7000 - 28.9800
Avg. Volume6,481,987
Market Cap41.203M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.2380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
  • PR Newswire

    iSpecimen Expands Support of COVID-19 Research with Availability of Sequenced Specimens to Detect Variants

    iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced the expansion of its supplier capabilities with the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants. The reference lab, a recent addition to the iSpecimen supplier network, has the capacity to sequence hundreds of COVID-19 positive swabs per week, providin

  • InvestorPlace

    ISPC Stock: What Is Going on With Little-Known iSpecimen Today?

    Today, Craig-Hallum initiated coverage of iSpecimen (NASDAQ:ISPC) with a “buy” rating and a price target of $20. This price target represents impressive upside of more than 120% from current prices. As a result, mention of ISPC stock on the popular financial site Stocktwits has increased by more than 21%. Source: Shutterstock What Is Going on With ISPC Stock Today? So what else do you need to know? Matthew Hewitt is the Craig-Hallum analyst who initiated coverage of ISPC stock. Hewitt believes t

  • Benzinga

    See why Craig-Hallum Is Bullish On iSpecimen

    Craig-Hallum initiated coverage of iSpecimen Inc (NASDAQ: ISPC) with a Buy rating and $20 price target. "Much the way Amazon has become the go-to platform for buyers and sellers of consumer goods," the analyst believes iSpecimen can become the go-to platform for human biospecimens, writes analyst Matthew Hewitt. The analyst notes that though the Company was founded in 2009, it has only recently reached a critical mass of buyers and sellers, with revenue for 2021 on track to be nearly triple the